PPM1D and breast carcinoma: We have found that GSK2830371 administered at doses that specifically block WIP1 activity does not affect proliferation of nontransformed cells but impairs proliferation of breast cancer cells with amplified PPM1D. MCF7 cells treated with GSK2830371 accumulate over time in the G2 phase of the cell cycle.